Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
Summary First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, posit...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2019-01, Vol.184 (2), p.202-214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 214 |
|---|---|
| container_issue | 2 |
| container_start_page | 202 |
| container_title | British journal of haematology |
| container_volume | 184 |
| creator | Bröckelmann, Paul J. McMullen, Suzanne Wilson, J Ben Mueller, Kerstin Goring, Sarah Stamatoullas, Aspasia Zagadailov, Erin Gautam, Ashish Huebner, Dirk Dalal, Mehul Illidge, Tim |
| description | Summary
First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography‐driven strategies and ABVD or BEACOPP variants incorporating the antibody‐drug conjugate brentuximab vedotin (BV) or anti‐PD1 antibodies are under investigation in advanced‐stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV‐AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross‐sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression‐free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5‐year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians’ recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians’ treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients. |
| doi_str_mv | 10.1111/bjh.15566 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6585631</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2165011418</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4436-8c7758b869954fa7b51aa815f3d543b67008e03fda506a6dc262b7603a34df4b3</originalsourceid><addsrcrecordid>eNp1kc1u1DAURi0EokNhwQsgS2xAIq0d_ySzQYKKdoBKsKBr6yZ2Jh4cO7UzrbJjwQPwjDwJnk6pAAlvbMnnHt_rD6GnlBzRvI6bTX9EhZDyHlpQJkVRUk7vowUhpCoo4fUBepTShhDKiKAP0QEjJVsu63KBvn-GyRo_YfAaj_2cbGvB4zGazkTjW5NwFyLubEzTz28_nPUGT9HANOyKQodbBykXgcOroNdfrcduHsY-DIDz-czEAfz8Cp9GyLKbV6be4AtvJ6PxR-vXOgyP0YMOXDJPbvdDdHH67svJqjj_dPb-5M150XLOZFG3VSXqppbLpeAdVI2gADUVHdOCs0ZWhNSGsE6DIBKkbktZNpUkDBjXHW_YIXq9947bZjC6zSNEcGqMdoA4qwBW_X3jba_W4UpJUQvJaBa8uBXEcLk1aVKDTa1xDrwJ26TKXRyCl5xk9Pk_6CZso8_jZUoKQnNEdaZe7qk2hpTyp981Q4nayVTOVt1km9lnf3Z_R_4OMwPHe-DaOjP_36Tefljtlb8ACEewQQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2165011418</pqid></control><display><type>article</type><title>Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom</title><source>MEDLINE</source><source>Wiley Journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Bröckelmann, Paul J. ; McMullen, Suzanne ; Wilson, J Ben ; Mueller, Kerstin ; Goring, Sarah ; Stamatoullas, Aspasia ; Zagadailov, Erin ; Gautam, Ashish ; Huebner, Dirk ; Dalal, Mehul ; Illidge, Tim</creator><creatorcontrib>Bröckelmann, Paul J. ; McMullen, Suzanne ; Wilson, J Ben ; Mueller, Kerstin ; Goring, Sarah ; Stamatoullas, Aspasia ; Zagadailov, Erin ; Gautam, Ashish ; Huebner, Dirk ; Dalal, Mehul ; Illidge, Tim</creatorcontrib><description>Summary
First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography‐driven strategies and ABVD or BEACOPP variants incorporating the antibody‐drug conjugate brentuximab vedotin (BV) or anti‐PD1 antibodies are under investigation in advanced‐stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV‐AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross‐sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression‐free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5‐year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians’ recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians’ treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.15566</identifier><identifier>PMID: 30239982</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject><![CDATA[ABVD ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; BEACOPP ; Bleomycin ; Bleomycin - administration & dosage ; Bleomycin - adverse effects ; Children ; Cross-Sectional Studies ; Cyclophosphamide ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - adverse effects ; Dacarbazine ; discrete choice experiment ; Disease-Free Survival ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Etoposide ; Female ; Fertility ; France - epidemiology ; Germany - epidemiology ; Haematological Malignancy ; Hematology ; Hodgkin Disease - drug therapy ; Hodgkin Disease - mortality ; Hodgkin lymphoma ; Hodgkin's lymphoma ; Humans ; Infertility ; Lungs ; Lymphoma ; Male ; Medical personnel ; Middle Aged ; Monoclonal antibodies ; Neuropathy ; patient and physician preferences ; Patient Preference ; Patients ; PD-1 protein ; Physicians ; Positron emission tomography ; Practice Patterns, Physicians ; Prednisone ; Procarbazine ; Procarbazine - administration & dosage ; Procarbazine - adverse effects ; Research Paper ; Survival ; Survival Rate ; Targeted cancer therapy ; United Kingdom - epidemiology ; Vinblastine ; Vinblastine - administration & dosage ; Vinblastine - adverse effects ; Vincristine ; Vincristine - administration & dosage ; Vincristine - adverse effects]]></subject><ispartof>British journal of haematology, 2019-01, Vol.184 (2), p.202-214</ispartof><rights>2018 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd</rights><rights>2018 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>Copyright © 2019 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4436-8c7758b869954fa7b51aa815f3d543b67008e03fda506a6dc262b7603a34df4b3</citedby><cites>FETCH-LOGICAL-c4436-8c7758b869954fa7b51aa815f3d543b67008e03fda506a6dc262b7603a34df4b3</cites><orcidid>0000-0003-3315-4674</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.15566$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.15566$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30239982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bröckelmann, Paul J.</creatorcontrib><creatorcontrib>McMullen, Suzanne</creatorcontrib><creatorcontrib>Wilson, J Ben</creatorcontrib><creatorcontrib>Mueller, Kerstin</creatorcontrib><creatorcontrib>Goring, Sarah</creatorcontrib><creatorcontrib>Stamatoullas, Aspasia</creatorcontrib><creatorcontrib>Zagadailov, Erin</creatorcontrib><creatorcontrib>Gautam, Ashish</creatorcontrib><creatorcontrib>Huebner, Dirk</creatorcontrib><creatorcontrib>Dalal, Mehul</creatorcontrib><creatorcontrib>Illidge, Tim</creatorcontrib><title>Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography‐driven strategies and ABVD or BEACOPP variants incorporating the antibody‐drug conjugate brentuximab vedotin (BV) or anti‐PD1 antibodies are under investigation in advanced‐stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV‐AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross‐sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression‐free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5‐year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians’ recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians’ treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.</description><subject>ABVD</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>BEACOPP</subject><subject>Bleomycin</subject><subject>Bleomycin - administration & dosage</subject><subject>Bleomycin - adverse effects</subject><subject>Children</subject><subject>Cross-Sectional Studies</subject><subject>Cyclophosphamide</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Dacarbazine</subject><subject>discrete choice experiment</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Etoposide</subject><subject>Female</subject><subject>Fertility</subject><subject>France - epidemiology</subject><subject>Germany - epidemiology</subject><subject>Haematological Malignancy</subject><subject>Hematology</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - mortality</subject><subject>Hodgkin lymphoma</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Infertility</subject><subject>Lungs</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Medical personnel</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Neuropathy</subject><subject>patient and physician preferences</subject><subject>Patient Preference</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Physicians</subject><subject>Positron emission tomography</subject><subject>Practice Patterns, Physicians</subject><subject>Prednisone</subject><subject>Procarbazine</subject><subject>Procarbazine - administration & dosage</subject><subject>Procarbazine - adverse effects</subject><subject>Research Paper</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Targeted cancer therapy</subject><subject>United Kingdom - epidemiology</subject><subject>Vinblastine</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - adverse effects</subject><subject>Vincristine</subject><subject>Vincristine - administration & dosage</subject><subject>Vincristine - adverse effects</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAURi0EokNhwQsgS2xAIq0d_ySzQYKKdoBKsKBr6yZ2Jh4cO7UzrbJjwQPwjDwJnk6pAAlvbMnnHt_rD6GnlBzRvI6bTX9EhZDyHlpQJkVRUk7vowUhpCoo4fUBepTShhDKiKAP0QEjJVsu63KBvn-GyRo_YfAaj_2cbGvB4zGazkTjW5NwFyLubEzTz28_nPUGT9HANOyKQodbBykXgcOroNdfrcduHsY-DIDz-czEAfz8Cp9GyLKbV6be4AtvJ6PxR-vXOgyP0YMOXDJPbvdDdHH67svJqjj_dPb-5M150XLOZFG3VSXqppbLpeAdVI2gADUVHdOCs0ZWhNSGsE6DIBKkbktZNpUkDBjXHW_YIXq9947bZjC6zSNEcGqMdoA4qwBW_X3jba_W4UpJUQvJaBa8uBXEcLk1aVKDTa1xDrwJ26TKXRyCl5xk9Pk_6CZso8_jZUoKQnNEdaZe7qk2hpTyp981Q4nayVTOVt1km9lnf3Z_R_4OMwPHe-DaOjP_36Tefljtlb8ACEewQQ</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Bröckelmann, Paul J.</creator><creator>McMullen, Suzanne</creator><creator>Wilson, J Ben</creator><creator>Mueller, Kerstin</creator><creator>Goring, Sarah</creator><creator>Stamatoullas, Aspasia</creator><creator>Zagadailov, Erin</creator><creator>Gautam, Ashish</creator><creator>Huebner, Dirk</creator><creator>Dalal, Mehul</creator><creator>Illidge, Tim</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3315-4674</orcidid></search><sort><creationdate>201901</creationdate><title>Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom</title><author>Bröckelmann, Paul J. ; McMullen, Suzanne ; Wilson, J Ben ; Mueller, Kerstin ; Goring, Sarah ; Stamatoullas, Aspasia ; Zagadailov, Erin ; Gautam, Ashish ; Huebner, Dirk ; Dalal, Mehul ; Illidge, Tim</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4436-8c7758b869954fa7b51aa815f3d543b67008e03fda506a6dc262b7603a34df4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>ABVD</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>BEACOPP</topic><topic>Bleomycin</topic><topic>Bleomycin - administration & dosage</topic><topic>Bleomycin - adverse effects</topic><topic>Children</topic><topic>Cross-Sectional Studies</topic><topic>Cyclophosphamide</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Dacarbazine</topic><topic>discrete choice experiment</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Etoposide</topic><topic>Female</topic><topic>Fertility</topic><topic>France - epidemiology</topic><topic>Germany - epidemiology</topic><topic>Haematological Malignancy</topic><topic>Hematology</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - mortality</topic><topic>Hodgkin lymphoma</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Infertility</topic><topic>Lungs</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Medical personnel</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Neuropathy</topic><topic>patient and physician preferences</topic><topic>Patient Preference</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Physicians</topic><topic>Positron emission tomography</topic><topic>Practice Patterns, Physicians</topic><topic>Prednisone</topic><topic>Procarbazine</topic><topic>Procarbazine - administration & dosage</topic><topic>Procarbazine - adverse effects</topic><topic>Research Paper</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Targeted cancer therapy</topic><topic>United Kingdom - epidemiology</topic><topic>Vinblastine</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - adverse effects</topic><topic>Vincristine</topic><topic>Vincristine - administration & dosage</topic><topic>Vincristine - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bröckelmann, Paul J.</creatorcontrib><creatorcontrib>McMullen, Suzanne</creatorcontrib><creatorcontrib>Wilson, J Ben</creatorcontrib><creatorcontrib>Mueller, Kerstin</creatorcontrib><creatorcontrib>Goring, Sarah</creatorcontrib><creatorcontrib>Stamatoullas, Aspasia</creatorcontrib><creatorcontrib>Zagadailov, Erin</creatorcontrib><creatorcontrib>Gautam, Ashish</creatorcontrib><creatorcontrib>Huebner, Dirk</creatorcontrib><creatorcontrib>Dalal, Mehul</creatorcontrib><creatorcontrib>Illidge, Tim</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bröckelmann, Paul J.</au><au>McMullen, Suzanne</au><au>Wilson, J Ben</au><au>Mueller, Kerstin</au><au>Goring, Sarah</au><au>Stamatoullas, Aspasia</au><au>Zagadailov, Erin</au><au>Gautam, Ashish</au><au>Huebner, Dirk</au><au>Dalal, Mehul</au><au>Illidge, Tim</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2019-01</date><risdate>2019</risdate><volume>184</volume><issue>2</issue><spage>202</spage><epage>214</epage><pages>202-214</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
First‐line treatments for classical Hodgkin lymphoma (HL) include ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPPescalated (escalated dose bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone). To further improve overall outcomes, positron emission tomography‐driven strategies and ABVD or BEACOPP variants incorporating the antibody‐drug conjugate brentuximab vedotin (BV) or anti‐PD1 antibodies are under investigation in advanced‐stage patients. The present study aimed to elicit preferences for attributes associated with ABVD, BEACOPPescalated and BV‐AVD (BV, adriamycin, vinblastine and dacarbazine) among patients and physicians. Cross‐sectional online discrete choice experiments were administered to HL patients (n = 381) and haematologists/oncologists (n = 357) in France, Germany and the United Kingdom. Included attributes were progression‐free survival (PFS), overall survival (OS), and the risk of neuropathy, lung damage, infertility and hospitalisation due to adverse events. Whereas 5‐year PFS and OS were the most important treatment attributes to patients, the relative importance of each attribute and preference weights for each level varied among physicians according to the description of the hypothetical patient for whom treatment was recommended. PFS and OS most strongly influenced physicians’ recommendations when considering young female patients who did not want children or young male patients. Infertility was more important to physicians’ treatment decision than PFS when considering young women with unknown fertility preferences, whereas hospitalisations due to adverse events played the largest role in treatment decisions for older patients.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>30239982</pmid><doi>10.1111/bjh.15566</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-3315-4674</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2019-01, Vol.184 (2), p.202-214 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6585631 |
| source | MEDLINE; Wiley Journals; Wiley Online Library (Open Access Collection) |
| subjects | ABVD Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects BEACOPP Bleomycin Bleomycin - administration & dosage Bleomycin - adverse effects Children Cross-Sectional Studies Cyclophosphamide Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Dacarbazine discrete choice experiment Disease-Free Survival Doxorubicin - administration & dosage Doxorubicin - adverse effects Etoposide Female Fertility France - epidemiology Germany - epidemiology Haematological Malignancy Hematology Hodgkin Disease - drug therapy Hodgkin Disease - mortality Hodgkin lymphoma Hodgkin's lymphoma Humans Infertility Lungs Lymphoma Male Medical personnel Middle Aged Monoclonal antibodies Neuropathy patient and physician preferences Patient Preference Patients PD-1 protein Physicians Positron emission tomography Practice Patterns, Physicians Prednisone Procarbazine Procarbazine - administration & dosage Procarbazine - adverse effects Research Paper Survival Survival Rate Targeted cancer therapy United Kingdom - epidemiology Vinblastine Vinblastine - administration & dosage Vinblastine - adverse effects Vincristine Vincristine - administration & dosage Vincristine - adverse effects |
| title | Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A35%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient%20and%20physician%20preferences%20for%20first%E2%80%90line%20treatment%20of%20classical%20Hodgkin%20lymphoma%20in%20Germany,%20France%20and%20the%20United%20Kingdom&rft.jtitle=British%20journal%20of%20haematology&rft.au=Br%C3%B6ckelmann,%20Paul%20J.&rft.date=2019-01&rft.volume=184&rft.issue=2&rft.spage=202&rft.epage=214&rft.pages=202-214&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.15566&rft_dat=%3Cproquest_pubme%3E2165011418%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2165011418&rft_id=info:pmid/30239982&rfr_iscdi=true |